Lon­za look­ing to build on 'd­if­fer­en­ti­at­ed ad­van­tage' in Covid-19, CD­MO mar­ket­place in 2021

It’s not new for Lon­za, the Swiss CD­MO near­ing its quasqui­cen­ten­ni­al an­niver­sary, to be in the up­per ech­e­lon of the biotech man­u­fac­tur­ing in­dus­try.

But 2020 — as it was for many CD­MOs — was a spe­cial year even by Lon­za’s stan­dards. The com­pa­ny inked a deal to pro­duce 1 bil­lion world­wide dos­es of Mod­er­na’s Covid-19 vac­cine and tapped phar­ma vet Pierre-Alain Ruffieux to lead its op­er­a­tions, moves which have al­lowed Lon­za to make a myr­i­ad of oth­er deals that will con­tin­ue to ramp up its glob­al pro­duc­tion ca­pac­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER